Press "Enter" to skip to content

American biopharmaceutical company Gilead Sciences Inc. Shares Crashes

Gilead Sciences Inc. shares shed 0.45% to $67.05 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.51% to 4,246.44 and the Dow Jones Industrial Average DJIA rising 0.20% to 33,945.58.Gilead Sciences Inc. closed $11.89 short of its 52-week high ($78.94), which the company reached on July 20th.The stock demonstrated a mixed performance when compared to some of its competitors Tuesday, as Johnson & Johnson JNJ fell 0.13% to $163.62, Merck & Co. Inc. MRK fell 0.73% to $76.19, and AbbVie Inc. ABBV fell 0.03% to $114.70.

Gilead Sciences Inc trading volume (4.8 M) remained 2.3 million below its 50-day average volume of 7.1 M.Gilead Sciences said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.

Remdesivir, the antiviral drug Gilead sells under the brand name Veklury, reduced mortality rates in hospitalized COVID-19 patients and increased their likelihood of being discharged by day 28 after a five-day regime.The announcement is based on three retrospective studies examining the real-world treatment of 98,654 hospitalized COVID-19 patients.In two of the studies, remdesivir reduced patients’ mortality risk by 54 percent and 23 percent.

Remdesivir has brought down the risk of mortality by a significant margin of 54% and 23% in two studies, Gilead said. The results, the drugmaker said, were consistently observed at different timeframes over the course of the pandemic and across geographies.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *